Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163462
Status:
COMPLETED
Last Update Posted:
2016-12-05
First Post:
2005-09-12
Brief Title:
Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma 6 to 11 y BY9010M1-206
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Comparison of Ciclesonide 80 mcg or 160 mcg Once Daily in the Evening and Fluticasone Propionate 100 mcg Twice Daily in the Morning and Evening in Pediatric Asthma Patients
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function symptoms and use of rescue medication in children with persistent asthma Ciclesonide will be inhaled once daily using one of the two dose levels fluticasone propionate will be inhaled at one dose level twice daily The study duration consists of a baseline period 2 to 4 weeks and a treatment period 12 weeks The study will provide further data on safety and tolerability of ciclesonide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None